Concerns About Blood Thinner Ticagrelor

‍Ticagrelor’s Effectiveness under Scrutiny: New analysis Raises Concerns

Concerns are mounting over the effectiveness of ticagrelor, a ⁢widely prescribed ⁤blood ⁢thinner, following⁤ a new analysis‍ published in ⁣the BMJ. ‍Ticagrelor, a ⁣P2Y12⁣ inhibitor, is ⁣used too‍ prevent blood clots in adults with a history of heart attacks or at⁢ risk of ⁣developing cardiovascular complications. It’s often prescribed alongside aspirin.

The⁤ drug’s approval by the FDA was based on the 2009 PLATO trial, a large-scale study involving over 18,000 patients from 43 countries. The trial concluded that ticagrelor was superior to clopidogrel, another P2Y12 inhibitor, in reducing ⁤the risk ⁤of death ⁣from ⁣vascular⁢ causes, heart attacks, or strokes. Though, American patients in the trial showed higher death rates with ticagrelor compared to clopidogrel, which AstraZeneca, the drug’s manufacturer, attributed ‍to higher aspirin dosages in this subgroup.

Subsequent studies have struggled to replicate these positive findings, raising questions about ticagrelor’s true efficacy. Notably, the BMJ analysis found that ticagrelor performed worse in trials overseen by independent contract research organizations compared to those conducted under AstraZeneca’s supervision.

Some experts suggest that the original PLATO trial may have been a statistical outlier, adn that subsequent trials failed ⁢to replicate its results because patients ⁣now⁢ have a lower⁤ risk of ischemic events due to advancements in secondary prevention ⁤and increased use ‍of stents.

However, the ⁣BMJ analysis also uncovered potential issues with the PLATO trial itself. The analysis‍ revealed omissions in the reported number of deaths and discrepancies in the causes and dates ⁣of death among patients.

AstraZeneca declined to comment on the BMJ’s criticisms.

Ticagrelor ⁢Under Fire: New Analysis Casts Doubt on Widely Prescribed Blood Thinner

newsdirect – A new analysis published⁣ in the BMJ has cast a shadow over ticagrelor, a popular blood thinner prescribed‍ to millions worldwide. The analysis questions the drug’s true⁤ effectiveness and raises concerns about the‍ validity of the original clinical trial that led to its ⁤approval.

Ticagrelor,a P2Y12 inhibitor,is commonly used to prevent blood clots in individuals wiht a history of heart‍ attacks or at risk of cardiovascular events. Its approval‍ by the FDA was based on the 2009 PLATO trial, which showed ticagrelor ⁣to be superior to clopidogrel, another P2Y12 inhibitor, in reducing ⁤the risk of death from vascular causes, heart attacks, and strokes.

However, the new BMJ analysis suggests that ticagrelor’s ⁤performance has been inconsistent across‍ various studies. Notably, the analysis found that ticagrelor performed worse in trials conducted by independent contract research organizations compared to those overseen by AstraZeneca, the drug’s manufacturer.

Adding fuel to the controversy, the analysis unearthed potential issues with the PLATO trial⁤ itself. Discrepancies were identified regarding the reported number of deaths and inconsistencies in the causes and dates of death among patients. Thes findings raise⁢ serious questions about the reliability of the data that underpinned ticagrelor’s approval.

While some experts⁣ propose⁤ that advancements in secondary prevention and wider use of stents have led to a lower risk of ischemic events, making it⁤ harder to replicate the PLATO trial’s initial⁤ positive results, the new BMJ analysis casts a long shadow⁤ of‍ doubt over the drug’s true efficacy.

AstraZeneca declined to comment on the ⁤BMJ’s criticisms. the controversy surrounding ticagrelor’s effectiveness highlights the ongoing need for rigorous scrutiny and independent analysis of clinical trials to ensure patients receive safe and effective⁢ treatments.